Vaccinex News

Express News | Vaccinex Inc - Qtrly Shr Loss $2.94

ReutersMay 15 18:02 ET

Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000

06:02 PM EDT, 05/15/2024 (MT Newswires) -- Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000

MT NewswiresMay 15 18:02 ET

Express News | Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

ReutersMay 15 18:00 ET

Vaccinex | 10-Q: Quarterly report

SEC announcementMay 15 17:26 ET · Announcements

12 Health Care Stocks Moving In Friday's After-Market Session

GainersLantern Pharma (NASDAQ:LTRN) shares rose 14.3% to $7.04 during Friday's after-market session. The company's market cap stands at $75.7 million. As per the press release, Q1 earnings came out ye

BenzingaMay 10 16:31 ET

12 Health Care Stocks Moving In Thursday's Intraday Session

GainersEmbecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out to

BenzingaMay 9 12:31 ET

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

GainersCyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shar

BenzingaApr 30 08:06 ET

Vaccinex Files to Sell 193,000 Shares of Common Stock for Holders

Seeking AlphaApr 26 17:32 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersProcessa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC

BenzingaApr 25 08:06 ET

Vaccinex(VCNX.US) 10% Shareholder Buys US$1,333.86 in Common Stock

$Vaccinex(VCNX.US)$ 10% Shareholder FRIEDBERG ALBERT purchased 282 shares of common stock on Apr 19, 2024 at an average price of $4.73 for a total value of $1,333.86. This transaction involves other r

moomoo NewsApr 22 17:16 ET

Vaccinex Faces Nasdaq Compliance Challenge

InvestingApr 12 16:44 ET

Express News | Vaccinex Q4 EPS $(0.33) Up From $(23.10) YoY

Moomoo 24/7Apr 2 22:59 ET

Vaccinex Files to Sell 433.5K Common Shares for Holders

Seeking AlphaApr 2 16:21 ET

Vaccinex Reports Q4 Results

Seeking AlphaApr 2 10:09 ET

Express News | Vaccinex Expects Topline Data For Phase 1/2a Randomized SIGNAL-AD Study Of Pepinemab For Alzheimer's Disease In Q3 2024

Moomoo 24/7Apr 2 08:45 ET

Express News | Vaccinex FY23 EPS $(43.68) Up From $(98.05) YoY, Revenue $570K Up From $275K YoY

Moomoo 24/7Apr 2 08:44 ET

Vaccinex 2023 Rev $570,000 >VCNX

Vaccinex 2023 Rev $570,000 >VCNX

Dow JonesApr 2 08:32 ET

Press Release: Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Vaccinex Reports 2023 Financial Results and Provides Corporate Update Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024 Company raised $17

Dow JonesApr 2 08:30 ET

Express News | Vaccinex, Inc. Announces $1.5M Registered Direct Offering And Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Moomoo 24/7Mar 27 08:31 ET

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's

GlobeNewswireMar 27 08:30 ET